Johnson & Johnson on Tuesday reported fourth-quarter profit above Wall Street expectations, helped by demand for its blockbuster psoriasis treatment Stelara and strength in its medical device unit.
The results come six months after J&J completed its spinoff of consumer health unit Kenvue, the company's biggest shake-up in its nearly 140-year history.
For savvy investors, hunting down undervalued stocks can mean unearthing overlooked stocks with big potential. In any market cycle, undervalued stocks are there, waiting to be scooped up at bargain pr
Johnson & Johnson is a healthcare giant that has increased its dividend for 61 consecutive years. Lowe's Companies has solid long-term prospects as the second-largest home improvement retailer.
Walgreens Boots Alliance disappointed investors with its recent dividend cut. There are other, more solid companies investors can rely on to pay a dividend.
Barron's 10 favorite Stocks for 2024 came-out 1/17/24. Their New-Year Roundtable, published 1/11/24, listed 8 stocks of note for 2024 and mentioned 15 more. Fortune published their 13 inflation-proof

Q4 Earnings Results Reflect Stability

05:51pm, Friday, 19'th Jan 2024
The picture emerging from the Q4 earnings season thus far has been good enough - not great, but definitely not bad either. Next week, we shift into a much higher gear, with 71 S&P 500 members schedule
Procter & Gamble and Johnson & Johnson are Dividend Kings with impressive dividend growth track records. Both companies have strong revenue growth prospects and solid free cash flow coverage of their
J&J's (JNJ) Innovative Medicines unit sales are expected to have been driven by drugs like Darzalex and Stelara. Surgical procedure recovery and new products are likely to have driven MedTech sales.
With so many question marks facing the viability of the equities sector, concerned investors may want to turn their attention to compelling healthcare stocks. Primarily, the sector benefits from perma
With so many question marks facing the viability of the equities sector, concerned investors may want to turn their attention to compelling healthcare stocks. Primarily, the sector benefits from perma
Johnson & Johnson (NYSE:JNJ) raised its full-year guidance after a strong third quarter which saw earnings beat expectations and its product pipeline advance. Still, Wall Street expects the New Brunsw
JNJ stock occupies a top spot in many portfolios due to its consistent performance and low volatility. But should we really and readily accept JNJ as a SWAN stock? A fresh look at Johnson & Johnson is
With Wall Street jubilant about avoiding a recession last year, investors may want to continue betting on the same horse, although here's the thing: targeting undervalued value stocks may offer a more
I recently purchased 15 shares of Johnson & Johnson, and discuss how it fits into my dividend cash machine. I emphasize the importance of dividend cash and compounding in building wealth over time. I
Click to get the best stock tips daily for free!

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE